1. Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival
- Author
-
Martin Schreder, Reinhard Stauder, Michael Girschikofsky, Martina Mitrovic, Werner Linkesch, Thamer Sliwa, Peter Valent, Richard Greil, Josef Thaler, Konstantin Schlick, Daniel Neureiter, Wolfgang R. Sperr, Ulrich Germing, Alois Lang, Sonja Burgstaller, Gudrun Placher-Sorko, Georg Theiler, Michael Pfeilstöcker, Lisa Pleyer, and Dietmar Geissler
- Subjects
Adult ,Male ,Oncology ,Antimetabolites, Antineoplastic ,Cancer Research ,medicine.medical_specialty ,Matched Pair Analysis ,Azacitidine ,Chronic myelomonocytic leukemia ,Matched-pair analysis ,Matched pair ,Monocyte count ,Overall response rate ,Internal medicine ,hemic and lymphatic diseases ,Activities of Daily Living ,medicine ,Humans ,Aged ,Aged, 80 and over ,CMML ,business.industry ,Cytogenetics ,Clinical course ,Leukemia, Myelomonocytic, Chronic ,Hematology ,Middle Aged ,medicine.disease ,Survival Analysis ,Immunology ,Disease Progression ,Female ,Austrian Azacitidine Registry ,business ,medicine.drug - Abstract
Recent data suggest that azacitidine may be beneficial in CMML. We report on 48 CMML-patients treated with azacitidine. Overall response rates were high (70% according to IWG-criteria, including 22% complete responses). Monocyte count and cytogenetics adversely affected survival, whereas age, WHO-type, FAB-type, and spleen size did not. Matched-pair analyses revealed a trend for higher two-year-survival for azacitidine as compared to best supportive care (62% vs. 41%, p=0.067) and longer OS for azacitidine first-line vs. hydroxyurea first-line (p=0.072, median OS 27.7 vs. 6.2 months). This report reinforces existing evidence that azacitidine is safe and efficacious in both myelodysplastic and myeloproliferative CMML.
- Full Text
- View/download PDF